About Presidio Pharmaceuticals
Presidio Pharmaceuticals is a Healthcare company based in San Francisco (United States) founded in 2006 by Omar Haffar. Small-molecule antiviral therapeutics for hepatitis C are developed. Presidio Pharmaceuticals has raised $91.93 million across 7 funding rounds from investors including New Leaf Venture Partners, Panorama Capital and Bay City Capital. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Microbial Testing. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and OpGen; 3 of its 3 listed competitors have raised funding.
Company details
Presidio Pharmaceuticals was founded in 2006 in San Francisco, United States, within the biopharmaceutical sector. Small-molecule antiviral therapeutics are developed, focusing on treatments for hepatitis C virus infections. The lead candidate, ravidasvir hydrochloride, is advanced for use in both healthy volunteers and patients, with antiviral activity observed in clinical evaluations. Operations center on therapeutic innovation for viral diseases.
- Headquarters San Francisco, United States
- Founders Omar Haffar
- SectorsHealthcare
- Website presidiopharma.com
- Social LinkedIn
- Total Equity Funding$91.93M (USD)
in 7 rounds
- Latest Funding Round$21.83M (USD), Series C
Jun 2014
- InvestorsNew Leaf Venture Partners
& 4 more
Funding Insights of Presidio Pharmaceuticals
Presidio Pharmaceuticals has successfully raised a total of $91.93M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $21.83 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $91.93M
- Total Rounds 7
- Last Round Series C — $21.83M
- First Round $26M
(Aug 2007)
- Investors Count 5
All 7 funding rounds of Presidio Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $21.83M | Series C | – | – | – |
| Oct 2012 | $7.98M | Series C | – | – | |
| Dec 2011 | $14.38M | Series C | – | – | – |
| Dec 2011 | Debt – Conventional | – | – | – | |
| Aug 2011 | $3M | Series B | – | – | – |
| Jul 2009 | $18.75M | Series B | – | New Leaf Venture Partners | – |
| Aug 2007 | $26M | Series B | – | – |
5 investors in total: 5 institutional.
Investors in Presidio Pharmaceuticals
Presidio Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Panorama Capital and Bay City Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Early & later stage venture capital firm investing in the US | panoramacapital.com | Campbell, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Early-stage investments in Canadian companies are made by Ventures West. | ventureswest.com | Vancouver, Canada | ||
| nexusmp.com |
Investor details for Presidio Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Presidio Pharmaceuticals
1 people are tracked at Presidio Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Omar Haffar | Co-Founder | Leadership |
Complete people profiles for Presidio Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Presidio Pharmaceuticals
3 dated milestones of Presidio Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Presidio Pharmaceuticals is founded.
- Funding First funding round of $26.0M.
- Funding Latest funding round, Series C, of $21.8M.
Competitors of Presidio Pharmaceuticals
Presidio Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and OpGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers |
Detailed competitors of Presidio Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Presidio Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Presidio Pharmaceuticals
Presidio Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Presidio Pharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Presidio Pharmaceuticals is a funded company, having raised a total of $91.93M across 7 funding rounds to date. The company's 1st funding round was a Series B of $26M, raised on Aug 2007.
Presidio Pharmaceuticals was founded in 2006 in San Francisco, United States, within the biopharmaceutical sector. Small-molecule antiviral therapeutics are developed, focusing on treatments for hepatitis C virus infections. The lead candidate, ravidasvir hydrochloride, is advanced for use in both healthy volunteers and patients, with antiviral activity observed in clinical evaluations. Operations center on therapeutic innovation for viral diseases.
Presidio Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and OpGen.
Presidio Pharmaceuticals has 5 investors. Key investors include New Leaf Venture Partners, Panorama Capital, Bay City Capital, Ventures West, and Nexus Medical Partners.